Current R&D Projects:

• Daunorubicin HCI (API):

  Anthracycline, CAS Number - 23541-50-6
  We are advancing the development of Daunorubicin HCI, an anthracycline antibiotic used in the treatment of various cancers. Our focus is on optimizing its production process to ensure high purity and stability.
• Cladribine (API):

  Nucleoside, CAS Number - 4291-63-8
  Our research includes the development of Cladribine, a chemotherapeutic agent used to treat certain types of leukemia and multiple sclerosis. We are dedicated to ensuring that our Cladribine API meets the highest quality standards.
• Cladribine – Premix:

  Nucleoside, CAS Number - n.a.
  In addition to the API, we are developing a premixed formulation of Cladribine to provide a ready-to-use solution for clinical use. This formulation aims to improve the convenience and accuracy of dosing for healthcare providers.
• Aldoxorubicin (API):

  Anthracycline, CAS Number - 1361644-26-9
  One of our key R&D projects is Aldoxorubicin, a tumor-targeted doxorubicin conjugate under investigation for the treatment of relapsed or refractory soft tissue sarcomas. Currently in late-stage clinical trials, our focus is on process optimization and the development of a stable crystalline form to enhance manufacturability and shelf-life.
• Camsirubicin (API):

  Anthracycline, CAS Number - 236095-24-2
  We are finalizing the development of Camsirubicin, a synthetic, non-cardiotoxic analogue of the anthracycline antibiotic doxorubicin. Used in Phase 1 and Phase 2 clinical trials for soft tissue sarcomas, our team has developed a novel synthetic route that achieves high yields and exceptional purity, supporting scalable production.
• Fludarabine Phosphate (API):

  Nucleoside, CAS Number - 75607-67-9
  Fludarabine Phosphate is a chemotherapeutic agent used in the treatment of leukemia and lymphoma. We are in the late stage of its development, utilizing a stereospecific enzyme- catalyzed synthesis approach. This methodology minimizes impurity formation and ensures that the final product meets the highest quality standards.
• Berubicin (API):

  Anthracycline, CAS Number - 293736-67-1
  Berubicin is a 4'-O-benzylated analogue of the anthracycline doxorubicin, capable of crossing the blood-brain barrier. It has been investigated in clinical trials for the treatment of recurrent glioblastoma multiforme. Our research is focused on the development of a new, selective, and cost-effective synthesis method suitable for industrial-scale production.
• Daunomustine (API):

  Anthracycline, CAS Number - n.a.
  Daunomustine is a chemotherapeutic agent that combines the anthracycline ring structure, as in doxorubicin, with a nitrosoureido functionality found in alkylating agents. It is primarily used for the treatment of canine cancers. We have established a robust laboratory-scale process that delivers high-quality Daunomustine and are exploring opportunities for scale-up.